Hafezi and colleagues developed a GMP-compatible protocol for efficient adenine base editing of TIM3 and TIGIT in tumor-infiltrating lymphocytes, resulting in enhanced expansion, cytokine production, and serial cytolytic capacity. This evidence concerns the gene TIGIT and neoplasm.